Alejandra B. Quintana
National University of Rosario
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alejandra B. Quintana.
Cell Transplantation | 2002
Silvana V. Spinelli; Joaquin V. Rodriguez; Alejandra B. Quintana; María Gabriela Mediavilla; Edgardo E. Guibert
Hepatocellular transplant may potentially be efficacious for the treatment of selected liver metabolic disorders and acute hepatic failure. On the other hand, the use of hepatocyte cold preservation techniques in these transplantation protocols would allow to have available cells at the right time and place and, consequently, make an optimal use of scarce human hepatocytes. In our experiments we evaluated the biodistribution and functionality of cold preserved hepatocytes transplanted in the spleen of syngeneic rats. Isolated hepatocytes were labeled with the fluorescent dye 5(6)-carboxyfluorescein diacetate succinimidyl-ester, cold-preserved in modified University of Wisconsin (UW) solution for 48 or 96 h, and then transplanted into the spleen. Recipient animals were euthanized at 0 and 3 h, and at 1, 2, 3, 5, 10, and 14 days after transplantation for tissue analysis. Labeled hepatocytes were clearly identifiable in the recipient tissues up to 14 days later. Fluorescence microscopy also showed no significant differences in biodistribution when either cold stored or freshly isolated hepatocytes were transplanted. In addition, functional activity of transplanted cells was demonstrated by immunohistochemical detection of albumin at levels comparable to those found in normal hepatocytes. Our findings establish that cold preserved hepatocytes appear morphologically and biochemically normal after intrasplenic transplantation. Consequently, it indicates that modified UW solution makes it possible to safety preserve hepatocytes for up to 96 h before transplantation, perhaps providing sufficient time for hepatocyte allocation and potential recipient preparation, if applicable clinically.
Cryobiology | 2009
Alejandra B. Quintana; Carlos D. Coda Zabetta; Norberto O. Baumgartner; María E. Biancardi; Victoria Bessone; Joaquin V. Rodriguez; María E. Mamprin; Graciela Furno; Edgardo E. Guibert; Virginia Sujatovich
Cryopreserved human cardiac valve allografts could suffer lethal damages if the temperature is elevated during cryostorage. This work describes the functional and morphological alterations suffered by human cardiac valve allografts after a gradual increment of the cryostorage temperature from -147 degrees C to -47 degrees C due to a technical failure. Three experimental groups of human pulmonary and aortic allografts were compared: fresh, cryopreserved (-147 degrees C) and cryopreserved with temperature changes from -147 degrees C up to -47 degrees C and back to -147 degrees C. Fibroblast functionality was studied to asses the degree of valvular damages. Collagen network was also analyzed with bright light field and polarized microscopy; an immunohistochemistry for procollagen I was performed and the MTT colorimetric assay was used to evaluate fibroblast mitochondrial enzymatic activity. Porcine heart grafts valves were used to set the MTT colorimetric assay. With bright light field microscopy, disorganized collagen network was seen together with interstitial edema in cryopreserved groups. Polarized microscopy showed that fresh allografts had abundant collagen type I and III, cryopreserved group had less amount of collagen type I and in allografts that suffered cryopreservation temperature elevation collagen type I synthesis could not been demonstrated. Procollagen I was present in fibroblast cytoplasm of fresh group, but it was diminished in cryopreserved group and was absent in the group that suffered temperature elevation. Temperature changes during the cryopreservation period of human cardiac valve allografts induced fibroblast activity reduction. When the cryopreservation temperature is elevated during cryostorage, fibroblasts lost their functionality and the allografts may be not suitable for transplant.
World Journal of Hepatology | 2016
María Dolores Pizarro; María Gabriela Mediavilla; Alejandra B. Quintana; Angel L. Scandizzi; Joaquin V. Rodriguez; María E. Mamprin
AIM To develop a simplified bioartificial liver (BAL) device prototype, suitable to use freshly and preserved liver Microorgans (LMOs) as biological component. METHODS The system consists of 140 capillary fibers through which goat blood is pumped. The evolution of hematocrit, plasma and extra-fiber fluid osmolality was evaluated without any biological component, to characterize the prototype. LMOs were cut and cold stored 48 h in BG35 and ViaSpan® solutions. Fresh LMOs were used as controls. After preservation, LMOs were loaded into the BAL and an ammonia overload was added. To assess LMOs viability and functionality, samples were taken to determine lactate dehydrogenase (LDH) release and ammonia detoxification capacity. RESULTS The concentrations of ammonia and glucose, and the fluids osmolalities were matched after the first hour of perfusion, showing a proper exchange between blood and the biological compartment in the minibioreactor. After 120 min of perfusion, LMOs cold preserved in BG35 and ViaSpan® were able to detoxify 52.9% ± 6.5% and 53.6% ± 6.0%, respectively, of the initial ammonia overload. No significant differences were found with Controls (49.3% ± 8.8%, P < 0.05). LDH release was 6.0% ± 2.3% for control LMOs, and 6.2% ± 1.7% and 14.3% ± 1.1% for BG35 and ViaSpan® cold preserved LMOs, respectively (n = 6, P < 0.05). CONCLUSION This prototype relied on a simple design and excellent performance. It’s a practical tool to evaluate the detoxification ability of LMOs subjected to different preservation protocols.
Journal of Surgical Research | 1999
Joaquin V. Rodriguez; Edgardo E. Guibert; Alejandra B. Quintana; Angel L. Scandizzi; Luciana L. Almada
Annals of Hepatology | 2005
Alejandra B. Quintana; Edgardo E. Guibert; Joaquin V. Rodriguez
Annals of Hepatology | 2003
Alejandra B. Quintana; Joaquin V. Rodriguez; Angel L. Scandizzi; Edgardo E. Guibert
Annals of Hepatology | 2002
Alejandra B. Quintana; Henrique L. Lenzi; Luciana L. Almada; Angel L. Scandizzi; Graciela Furno; Joaquin V. Rodriguez; Edgardo E. Guibert
Annals of Hepatology | 2011
Mandolino C; Pizarro; Alejandra B. Quintana; Joaquin V. Rodriguez; María E. Mamprin
Annals of Hepatology | 2004
Alejandra B. Quintana; Joaquin V. Rodriguez; Henrique L. Lenzi; Edgardo E. Guibert
Annals of Hepatology | 2015
Marina C. Vera; Gerardo B. Pisani; María E. Biancardi; Hebe Bottai; María de Luján Alvarez; Alejandra B. Quintana